The thalidomide tragedy is now, and always will be, part of Grünenthal's company history. Grünenthal and its family shareholders greatly regret the consequences of the thalidomide tragedy. It is a matter of moral importance to Grünenthal to be actively involved in charitable efforts to improve the situation of thalidomide-affected people on a sustainable basis. We seek to work together with those affected by thalidomide to devise projects for the provision of specific needs-based support.
Our position is clear: There is an established financial support system for people affected by Thalidomide throughout Europe. The Contergan foundation*, in which Grünenthal has paid more than 100 million Euros, supports affected individuals in 38 countries with monthly individual payments between 662 € and 7.480 € including those affected in Spain, provided that their mothers took a Thalidomide containing product from Grünenthal.
Grünenthal Pharma has set up a program to support the costs of the translations into German language of the relevant medical documents and applications of Spanish individuals willing to apply to the Contergan Foundation in Germany.